Search clinical trials for: BIBW 2948 BS

Total 347 results

Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Neoplasms
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Multiple Myeloma

United States
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

Healthy
Boehringer Ingelheim

Terminated

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Ovarian Neoplasms

Japan
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Breast Neoplasms

United States, Brazil, Colombia, Peru
Chroma Therapeutics

Terminated

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
University of Cologne
Boehringer Ingelheim

Completed

BIBF 1120 and RAD001 in Solid Tumors - Phase I (BARIS)

Solid Tumors

Germany
Second Affiliated Hospital, School of Medicine,...

Recruiting

Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Er Laser for the Treatment of Androgenetic Alopecia

Androgenetic Alopecia

China
Turku University Hospital
University of Turku

Completed

Novel Imaging in Staging of Primary Prostate Cancer (PROSTAGE)

High Risk Prostate Cancer

Finland
xjpfW
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; First Hospital... and other collaborators

Completed

A Study of the Efficacy of Erbium:YAG 2940nm in Combination With 1064nm Laser on Facial Rejuvenation

Facial Rejuvenation
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV... and other conditions

United States
Boehringer Ingelheim

Completed

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Breast Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Healthy
Columbia University
Boehringer Ingelheim

Withdrawn

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Esophageal Cancer | Gastrooesophageal Cancer | HER-2 Positive Gastric Cancer
University of Zurich

Unknown

Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep

Interstitial Lung Disease | Precapillary Pulmonary Hypertension

Switzerland
Novartis Pharmaceuticals

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
Pfizer

Completed

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Psoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic Psoriasis

Japan
Boehringer Ingelheim

Completed

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

Spain
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; Curis, Inc.

Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Stomach Cancer | Gastric Cancer | Esophageal Cancer | Gastroesophageal Junction Cancer | Esophagus Cancer

United States
Pfizer

Completed

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Crohn's Disease | Ulcerative Colitis

Japan
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

Coronavirus Infections | COVID-19

United Arab Emirates
University of California, Davis
National Cancer Institute (NCI)

Completed

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Vaxxinity, Inc.
Syneos Health; Coalition for Epidemic Preparedness Innovations

Active, not recruiting

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

COVID-19 Vaccines

Philippines, United States, Panama
University of Magdeburg
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) and Vinorelbine

Carcinoma Breast Stage IV

Germany
Stemirna Therapeutics

Active, not recruiting

mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs

Efficacy | Safety | Immunogenicity

Lao People's Democratic Republic
Boehringer Ingelheim

Completed

Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers

Healthy
University of Zurich

Completed

Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance

Interstitial Lung Disease | Precapillary Pulmonary Hypertension

Switzerland
JI-YOUN HAN
National Cancer Center, Korea

Completed

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Recurrent

Korea, Republic of
Boehringer Ingelheim

Completed

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Neoplasms

France, Germany
Boehringer Ingelheim

Completed

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Tumors
Boehringer Ingelheim

Completed

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Malignant Solid Tumour

Germany
National Cancer Center, Korea
Boehringer Ingelheim

Completed

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Non-small Cell Lung Cancer

Korea, Republic of
Mansoura University

Unknown

Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study

Weight Loss | Morbid Obesity | Tolerance

Egypt
Boehringer Ingelheim

Completed

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Neoplasms

Italy
Boehringer Ingelheim

Completed

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Tumors
Boehringer Ingelheim

Completed

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

Spain, Belgium, Canada, Germany, China, United Kingdom, Australia, Ireland, Italy, Mexico, Netherlands, Portugal, Argentina, France, Russian Federation, Greece, Czechia, Brazil, Bulgaria, Chile, Hungary
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

Pulmonary Fibrosis

United States, Australia, Belgium, China, Czech Republic, France, Germany, India, Ireland, Israel, Italy, Japan, United Kingdom
Boehringer Ingelheim

Completed

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
National Cancer Institute (NCI)

Recruiting

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Prof. Dr. Wolfgang Wick

Terminated

NOA-12: BIBF1120 and R-RT in Glioblastoma

Glioblastoma Multiforme

Germany
Boehringer Ingelheim

Completed

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Breast Neoplasms

Korea, Republic of, Spain, Canada, Germany, Singapore, China, United Kingdom, Taiwan, Israel, United States, Australia, Slovenia, Italy, Brazil, India, Czechia, Netherlands, Ireland, Poland, Belarus, Belgium, Portugal, Russian Federation and more
Boehringer Ingelheim

Completed

Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects

Healthy

Search clinical trials for: BIBW 2948 BS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations